Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2026-03-08 @ 11:03 PM
Study NCT ID:
NCT01605227
Status:
COMPLETED
Last Update Posted:
2018-03-14
First Post:
2012-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Sponsor:
Exelixis
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-07
Start Date Type:
None
Primary Completion Date:
2014-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-03
Completion Date Type:
ACTUAL
First Submit Date:
2012-05-22
First Submit QC Date:
None
Study First Post Date:
2012-05-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-05-23
Results First Submit QC Date:
None
Results First Post Date:
2018-03-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-02-14
Last Update Post Date:
2018-03-14
Last Update Post Date Type:
ACTUAL